Immune Tolerance to Tumor Antigens Occurs in a Specialized Environment of the Spleen

Cell Reports

Volumn 2, Issue 3, 2012, Pages 628-639

  Ugel, Stefano ^a,b,g   Peranzoni, Elisa ^b,g   Desantis, Giacomo ^a   Chioda, Mariacristina ^b   Walter, Steffen ^c   Weinschenk, Toni ^c   Ochando, Jordi C ^d   Cabrelle, Anna ^e   Mandruzzato, Susanna ^a,b   Bronte, Vincenzo ^f  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c IMMATICS BIOTECHNOLOGIES GMBH   (Germany)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

^f UNIVERSITY HOSPITAL OF VERONA   (Italy)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD11B ANTIGEN; CELL PROTEIN; CHEMOKINE RECEPTOR CCR2; CYCLOPHOSPHAMIDE; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMA 901; IMIQUIMOD; MONOCYTE CHEMOTACTIC PROTEIN 1; OXALIPLATIN; PROTEIN GR 1; PROTEIN LY6C; RECOMBINANT INTERLEUKIN 2; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CD8+ T LYMPHOCYTE; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; IMMUNOLOGICAL TOLERANCE; KIDNEY CANCER; KIDNEY CARCINOMA; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MONOCYTE; MOUSE; MULTICENTER STUDY; MYELOID PROGENITOR CELL; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOLID TUMOR; SPLEEN; SPLENECTOMY; TREATMENT RESPONSE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC MEMORY; MICE; MONOCYTES; NEOPLASMS; SPLEEN;

EID: 84866920497     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2012.08.006     Document Type: Article

References (43)

1. Biermann H., Pietz B., Dreier R., Schmid K.W., Sorg C., Sunderkötter C. Murine leukocytes with ring-shaped nuclei include granulocytes, monocytes, and their precursors. J. Leukoc. Biol. 1999, 65:217-231.
2. Bronte V., Wang M., Overwijk W.W., Surman D.R., Pericle F., Rosenberg S.A., Restifo N.P. Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J. Immunol. 1998, 161:5313-5320.
3. Bronte V., Chappell D.B., Apolloni E., Cabrelle A., Wang M., Hwu P., Restifo N.P. Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J. Immunol. 1999, 162:5728-5737.
4. Chalmin F., Ladoire S., Mignot G., Vincent J., Bruchard M., Remy-Martin J.P., Boireau W., Rouleau A., Simon B., Lanneau D., et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J. Clin. Invest. 2010, 120:457-471.
5. Cortez-Retamozo V., Etzrodt M., Newton A., Rauch P.J., Chudnovskiy A., Berger C., Ryan R.J., Iwamoto Y., Marinelli B., Gorbatov R., et al. Origins of tumor-associated macrophages and neutrophils. Proc. Natl. Acad. Sci. USA 2012, 109:2491-2496.
6. Dolcetti L., Peranzoni E., Bronte V. Measurement of myeloid cell immune suppressive activity. Curr. Protoc. Immunol. 2010, Chapter 14. Unit 14.17.
7. Dolcetti L., Peranzoni E., Ugel S., Marigo I., Fernandez Gomez A., Mesa C., Geilich M., Winkels G., Traggiai E., Casati A., et al. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur. J. Immunol. 2010, 40:22-35.
8. Fridlender Z.G., Buchlis G., Kapoor V., Cheng G., Sun J., Singhal S., Crisanti M.C., Wang L.C., Heitjan D., Snyder L.A., Albelda S.M. CCL2 blockade augments cancer immunotherapy. Cancer Res. 2010, 70:109-118.
9. Fridlender Z.G., Kapoor V., Buchlis G., Cheng G., Sun J., Wang L.C., Singhal S., Snyder L.A., Albelda S.M. Monocyte chemoattractant protein-1 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ cells. Am. J. Respir. Cell Mol. Biol. 2011, 44:230-237.
10. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9:162-174.
11. Gabrilovich D.I., Ostrand-Rosenberg S., Bronte V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 2012, 12:253-268.
12. Galluzzi L., Senovilla L., Zitvogel L., Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat. Rev. Drug Discov. 2012, 11:215-233.
13. Gattinoni L., Powell D.J., Rosenberg S.A., Restifo N.P. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 2006, 6:383-393.
14. Geissmann F., Jung S., Littman D.R. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003, 19:71-82.
15. Ghiringhelli F., Larmonier N., Schmitt E., Parcellier A., Cathelin D., Garrido C., Chauffert B., Solary E., Bonnotte B., Martin F. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 2004, 34:336-344.
16. Ghiringhelli F., Menard C., Puig P.E., Ladoire S., Roux S., Martin F., Solary E., Le Cesne A., Zitvogel L., Chauffert B. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 2007, 56:641-648.
17. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
18. Khanna K.M., McNamara J.T., Lefrançois L. In situ imaging of the endogenous CD8 T cell response to infection. Science 2007, 318:116-120.
19. Klebanoff C.A., Khong H.T., Antony P.A., Palmer D.C., Restifo N.P. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol. 2005, 26:111-117.
20. Kusmartsev S., Nagaraj S., Gabrilovich D.I. Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J. Immunol. 2005, 175:4583-4592.
21. Lesokhin A., Hohl T.M., Kitano S., Cortez C., Hirschhorn-Cymerman D., Avogadri F., Rizzuto G.A., Lazarus J.J., Pamer E.G., Houghton A.N., et al. Monocytic CCR2+ myeloid derived suppressor cells promote immune escape by limiting activated CD8 T cell infiltration into the tumor microenvironment. Cancer Res. 2011, 72. 876-86.
22. Lesokhin A.M., Hohl T.M., Kitano S., Cortez C., Hirschhorn-Cymerman D., Avogadri F., Rizzuto G.A., Lazarus J.J., Pamer E.G., Houghton A.N., et al. Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res. 2012, 72:876-886.
23. Leuschner F., Dutta P., Gorbatov R., Novobrantseva T.I., Donahoe J.S., Courties G., Lee K.M., Kim J.I., Markmann J.F., Marinelli B., et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat. Biotechnol. 2011, 29:1005-1010.
24. Ma Y., Kepp O., Ghiringhelli F., Apetoh L., Aymeric L., Locher C., Tesniere A., Martins I., Ly A., Haynes N.M., et al. Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin. Immunol. 2010, 22:113-124.
25. Marigo I., Bosio E., Solito S., Mesa C., Fernandez A., Dolcetti L., Ugel S., Sonda N., Bicciato S., Falisi E., et al. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 2010, 32:790-802.
26. Molon B., Ugel S., Del Pozzo F., Soldani C., Zilio S., Avella D., De Palma A., Mauri P., Monegal A., Rescigno M., et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J. Exp. Med. 2011, 208:1949-1962.
27. Nagaraj S., Gupta K., Pisarev V., Kinarsky L., Sherman S., Kang L., Herber D.L., Schneck J., Gabrilovich D.I. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat. Med. 2007, 13:828-835.
28. Ogawa M., Matsuzaki Y., Nishikawa S., Hayashi S., Kunisada T., Sudo T., Kina T., Nakauchi H., Nishikawa S. Expression and function of c-kit in hemopoietic progenitor cells. J. Exp. Med. 1991, 174:63-71.
29. Qian B.Z., Li J., Zhang H., Kitamura T., Zhang J., Campion L.R., Kaiser E.A., Snyder L.A., Pollard J.W. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011, 475:222-225.
30. Restifo N.P., Dudley M.E., Rosenberg S.A. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 2012, 12:269-281.
31. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570.
32. Shi C., Pamer E.G. Monocyte recruitment during infection and inflammation. Nat. Rev. Immunol. 2011, 11:762-774.
33. Shi C., Jia T., Mendez-Ferrer S., Hohl T.M., Serbina N.V., Lipuma L., Leiner I., Li M.O., Frenette P.S., Pamer E.G. Bone marrow mesenchymal stem and progenitor cells induce monocyte emigration in response to circulating toll-like receptor ligands. Immunity 2011, 34:590-601.
34. Sica A., Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 2007, 117:1155-1166.
35. Solito S., Falisi E., Diaz-Montero C.M., Doni A., Pinton L., Rosato A., Francescato S., Basso G., Zanovello P., Onicescu G., et al. A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood 2011, 118:2254-2265.
36. Sonda N., Chioda M., Zilio S., Simonato F., Bronte V. Transcription factors in myeloid-derived suppressor cell recruitment and function. Curr. Opin. Immunol. 2011, 23:279-285.
37. Swirski F.K., Nahrendorf M., Etzrodt M., Wildgruber M., Cortez-Retamozo V., Panizzi P., Figueiredo J.L., Kohler R.H., Chudnovskiy A., Waterman P., et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 2009, 325:612-616.
38. Ugel S., Scarselli E., Iezzi M., Mennuni C., Pannellini T., Calvaruso F., Cipriani B., De Palma R., Ricci-Vitiani L., Peranzoni E., et al. Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes. Blood 2010, 115:1374-1384.
39. Vincent J., Mignot G., Chalmin F., Ladoire S., Bruchard M., Chevriaux A., Martin F., Apetoh L., Rébé C., Ghiringhelli F. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010, 70:3052-3061.
40. Walter S., Weinschenk T., Stenzl A., Zdrojowy R., Pluzanska A., Szczylik C., Staehler M., Brugger W., Dietrich P.Y., Mendrzyk R., et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat. Med. 2012, Published online July 29, 2012. 10.1038/nm.2883.
41. Wrzesinski C., Restifo N.P. Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy. Curr. Opin. Immunol. 2005, 17:195-201.
42. Wrzesinski C., Paulos C.M., Kaiser A., Muranski P., Palmer D.C., Gattinoni L., Yu Z., Rosenberg S.A., Restifo N.P. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J. Immunother. 2010, 33:1-7.
43. Zitvogel L., Kepp O., Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat. Rev. Clin. Oncol. 2011, 8:151-160.